Esophageal cancer is one of the leading causes of cancer-related deaths worldwide, with approximately 600,000 cases per year globally, making it the seventh most common cancer and the sixth deadliest cancer. At Alfa Cytology, we are committed to helping our clients unravel the complexity of esophageal cancer by providing integrated preclinical research solutions.
Introduction to Gallbladder Cancer
Gallbladder cancer (GBC) is the third most common malignant tumour of the gastrointestinal tract and the most common malignant tumour of the biliary tract in the world, with an overall incidence of only 2.5 per 100,000, but with an extremely poor prognosis, with a 5-year survival rate of only 5% and an average survival of about 6 months.
Fig.1 Age standardized (World) incidence rates, Gallbladder, females, all ages. (Sung, H., et al., 2021)
Globally, GBC incidence is higher in women than in men, with incidence rate ratios of ~2 in the Americas. For example, in the USA, the age-adjusted incidence rate is 1.9/100,000 in women compared with 1.1/100,000 in men.
Therapy Development for Gallbladder Cancer
The therapeutic options for gallbladder cancer depend on various factors, including the stage of the cancer, the location and extent of the tumor. The main treatment modalities for gallbladder cancer include surgery, chemotherapy, radiation therapy, and targeted therapy.
Phase III clinical trials of first-line therapies for gallbladder cancer are listed below.
| Trial |
Patient number |
Treatment regimens |
OS (months) |
Hazard ratio
(95% CI) |
| ABC-02 |
149 |
Gem |
8.1 |
0.61 (0.42–0.89) |
| Gem+Cis |
11.7 |
| JCOG1113 |
137 |
Gem+Cis |
13.4 |
0.97 (0.67–1.4) |
| Gem+S1 |
15.1 |
| GEMOX±erlotinib |
82 |
GEMOX |
9.5 |
0.99 (0.63–1.58) |
| GEMOX+erlotinib |
9.5 |
Our Services
This surge in market size underscores the increasing demand for effective and innovative therapy solutions. At Alfa Cytology, we are dedicated to the development of diagnostic and therapeutic methods for gallbladder cancer, providing a comprehensive, state-of-the-art service to a wide range of clients.
Modeling Services of Gallbladder Cancer
Studying the complexities of gallbladder cancer requires the utilization of robust and clinically relevant experimental models. At Alfa Cytology, we have established a comprehensive array of in vitro and in vivo models that faithfully recapitulate the diverse facets of gastric malignancies, from the genomic and molecular landscapes to the intricate tumor-microenvironment interactions.
| Types |
In Vitro Models |
In Vivo Models |
| Models |
|
- Patient-Derived Xenografts
- Genetically Engineered Mouse Models
|
| Applications |
- High-Throughput Drug Screening
- Target Validation
- Evaluation of Novel Therapeutic Strategies
|
|
At Alfa Cytology, we are committed to being at the forefront of gallbladder cancer research and development, offering comprehensive and advanced solutions for the treatment of this challenging disease. Our extensive experience in preclinical research, biomarker discovery, histological analysis, therapy development and other services enables us to provide a more comprehensive service to our clients. If you would like to learn more about our gallbladder cancer R&D program or have any questions about our comprehensive services, please don't hesitate to contact us.
Reference
- Sung, H., et al.; (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
For research use only.
Related Services
